RESUMO
As one of the most important products of complement activation, C5a, after binding to ts receptors (C5aR), has been considered to be involved n the pathology of numerous inflammatory diseases, such as acute ung njury, sepsis, rheumatoid arthritis and glomerular nephritis. Therefore, the focus of current studies on how to block C5a and C5aR signal transduction for dampening the inflammatory reaction. Recently, several antagonists of C5a and C5aR were reported, including C5a antibody, small molecule human C5aR antagonists, C5a antisense peptide, C5a mutant and the complex of chemotaxis inhibitory protein of Staphylococcus aureus with C5aR. In this review, the structure and function of C5a and C5aR, and the advances n the research on their antagonists are summarized.